Trial Profile
Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Apr 2020
Price :
$35
*
At a glance
- Drugs Florbetapir-18 MNI 1126 (Primary)
- Indications Alzheimer's disease; Parkinson's disease
- Focus Diagnostic use
- Sponsors Invicro
- 13 Apr 2020 Status changed from recruiting to completed.
- 06 Sep 2019 Planned End Date changed from 7 May 2019 to 7 May 2020.
- 06 Sep 2019 Planned primary completion date changed from 7 May 2019 to 7 May 2020.